Table 1

Summary of incentives and disincentives for POC CRP adoption by stakeholder group

StakeholdersReasons FOR adoptionReasons AGAINST adoptionRecommendations/next steps
NHSEarly intervention by GP; less hospital referrals; NICE pneumonia guidelines recommendations; evidence of reduction in unnecessary antibiotics prescription when CRP test results are usedFunding mechanism needs to balance encouraging adoption of POC CRP and overuseClear POC CRP user guideline necessary
General PractitionersIncreased diagnostic confidence; increased decision-making support especially when in doubt; improved communication with patients; improved access to test that overcomes geographical distance; early adopters/opinion leaders continue to publish evidence that favours wider-scale adoptionBehaviour inertia and risk aversions; perception of the test taking up too much time; POC CRP expensive to take upPerception of time can be corrected—successful adoption model exists; further evidence required on clinical utility at individual GP practice
LaboratoriesActive role in quality control, training, maintenance of POC devices that are consistent with the future of laboratory servicesIncome loss due to not performing CRP tests, but the impact presumably smallFunding route carefully managed to encourage and ensure quality maintenance role by clinical laboratories
  • CRP, C reactive protein; GP, general practitioner; NHS, National Health Service; NICE, National Institute of Health and Care Excellence; POC, point-of-care.